Timing of quality of life (QoL) assessments as a source of error in oncological trials

Journal of Advanced Nursing

Volumn 35, Issue 5, 2001, Pages 709-716

  Hakamies Blomqvist, Liisa ^a   Luoma, M L ^a   Sjostrom J ^b   Pluzanska, A ^c   Sjodin M ^d   Mouridsen, H ^e   Ostenstad B ^f   Mjaaland, I ^g   Ottosson, S ^h   Bergh, J ⁱ   Malmstrom P O ^j   Blomqvist, C ^k  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e Rigshospitalet   (Denmark)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g STAVANGER UNIVERSITY HOSPITAL   (Norway)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j LUND UNIVERSITY HOSPITAL   (Sweden)

^k UPPSALA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Advanced breast cancer; Assessment timing; Chemotherapy; Methodology; Quality of life; Study nurses; Trial

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; EPIDEMIOLOGY; FEMALE; HEALTH STATUS; HUMAN; INFORMATION PROCESSING; METHODOLOGY; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STANDARD; TIME; VALIDATION STUDY;

ACTIVITIES OF DAILY LIVING; ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; DATA COLLECTION; FEMALE; HEALTH STATUS; HUMANS; MULTICENTER STUDIES; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 18044400846     PISSN: 03092402     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2648.2001.01903.x     Document Type: Article

References (27)

1. Aaronson N., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N., Filiberti A., Flechtner H., Fleishman S., de Haes J., Kaasa S., Klee M., Osoba D., Razavi D., Rofe P., Schraub S., Sneeuw K., Sullivan M. & Takeda F. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of National Cancer Institute 85, 365-376.
2. Anderson H. & Palmer M. (1998) Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. British Journal of Cancer 2, 9-14.
3. Bernhard J., Cella D., Coates A., Fallowfield L., Ganz P., Moinpour C., Mosconi P., Osoba D., Simes J. & Hurny C. (1998a) Missing quality of life data in cancer clinical trials: serious problems and challenges. Statistics in Medicine 17, 517-532.
4. Bernhard J., Peterson H., Coates A., Gusset H., Isley M., Hinkle R., Gelber R., Castiglione-Gertsch M. & Hurny C. (1998b) Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data. Statistics in Medicine 17, 587-601.
5. Fayers P., Aaronson N., Bjordal K. & Sullivan M. (1995) EORTC QLQ-C30 Scoring Manual. EORTC Study Group on Quality of Life, Brussels.
6. Fayers P., Hopwood P., Harvey A., Girling D., Machin D. & Stephens R. (1997) Quality of life assessment in clinical trials -guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office. European Journal of Cancer 33, 20-28.
7. Giaccone G., Splinter T., Debruyne C., Kho G., Lianes P., van Zandwijk N., Pennucci M., Scagliotti G., van Meerbeeck J., van Hoesel Q., Curran D., Sahmoud T. & Postmus P. (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of Clinical Oncology 16, 2133-2141.
8. Groenvold M. (1999) Methodological issues in the assessment of health-related quality of life in palliative care trials. Acta Anaesthesiologica Scandinavica 43, 948-953.
9. de Haes J., Curran D., Young T., Bottomley A., Flechtner H., Aaronson N., Blazeby J., Bjordal K., Brandberg Y., Greimel E., Maher J., Sprangers M. & Cull A. (2000) Quality of life evaluation in oncological clinical trials - the EORTC model. European Journal of Cancer 36, 821-825.
10. Hakamies-Blomqvist L., Luoma M.-L., Sjöström J., Pluzanska A., Sjödin M., Mouridsen H., Ostenstad B., Mjaaland I., Ottosson-Lönn S., Bergh J., Malmström P.-O. & Blomqvist C. (2000) Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group. European Journal of Cancer 36, 1411-1417.
11. Helsing M., Bergman B., Thaning L. & Hero U. (1998) Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. European Journal of Cancer 34, 1036-1044.
12. Hürny C., Bernhard J., Joss R., Willems Y., Cavalli F., Kiser J., Brunner K., Favre S., Alberto P., Glaus A., Senn H., Schatsmann E., Ganz P. & Mezger U. (1992) Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer - a lesson from the real world - the Swiss Group for Clinical Cancer Research SAKK. Annals of Oncology 3, 825-831.
13. Hürny C., Bernhard J., Coates A., Castiglione M., Peterson H., Gelber R., Rudenstam C., Goldhirsch A. & Senn H. (1994) Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group. Annals of Oncology 5, 65-74.
14. Kiebert G. (1997) Quality of life as an outcome in EORTC clinical trials. European Journal of Cancer 33, s31-s34.
15. Kiebert G., Curran D. & Aaronson N. (1998) Quality of life as an endpoint in EORTC clinical trials. European Organization for Research and Treatment for Cancer. Statistics in Medicine 17, 561-569.
16. Klee M., King M., Machin D. & Hansen H. (2000) A clinical model for quality of life assessment in cancer patients receiving chemotherapy. Annals of Oncology 11, 23-30.
17. Nabholtz J., Senn H., Bezwoda W., Melnychuk D., Deschenes L., Douma J., Vandenberg T., Rapoport B., Rosso R., Trillet-Lenoir V., Drbal J., Molino A., Nortier J., Richel D., Nagykalnai T., Siedlecki P., Wilking N., Genot J., Hupperets P., Pannuti F., Skarlos D., Tomiak E., Murawsky M., Alakl M. & Aapro M. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. Journal of Clinical Oncology 17, 1413-1424.
18. Osoba D. (1999a) What has been learned from measuring health-related quality of life in clinical oncology. European Journal of Cancer 35, 1565-1570.
19. Osoba D. (1998b) Guidelines for measuring health-related quality of life in clinical trials. In Quality of Life Assessment in Clinical Trials: Methods and Practice (Staguet M. & Fayers P. eds), Oxford University Press, New York, pp. 19-35.
20. Osoba D., Rodrigues G., Myles J., Zee B. & Pater J. (1998a) Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology 16, 139-144.
21. Osoba D., Tannock I., Ernst D. & Neville A. (1999b) Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. Journal of Clinical Oncology 17, 1654-1663.
22. Osoba D. & Zee B. (1998) Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group. Statistics in Medicine 17, 603-612.
23. Pater J., Osoba D., Zee B., Lofters W., Gore M., Dempsey E., Palmer M. & Chin C. (1998) Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. Quality of Life Research 7, 273-278.
24. Priestman T. & Baum M. (1976) Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1, 899-900.
25. Sjöström J., Blomqvist C., Mouridsen H., Pluzanska A., Ottosson Lönn S., Bengtsson N.-O., Østenstad B., Mjaaland I., Palm-Sjövall M., Wist E., Valvere E., Anderson H. & Bergh J. (1999) Docetaxel compared to sequential methotrexate-5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with cross-over on progression by the Scandinavian Breast Group. European Journal of Cancer 35, 1194-1201.
26. Webb A., Cunningham D., Scarffe J.H., Harper P., Norman A., Joffe J., Hughes M., Mansi J., Findlay M., Hill A., Oates J., Nicolson M., Hickish T., O'Brien M., Iveson T., Watson M., Underhill C., Wardley A. & Meehan M. (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology 15, 261-267.
27. Young T., de Haes H., Curran D., Fayers P. & Brandberg Y. (1999) Guidelines for Assessing Quality of Life in EORTC Trials. EORTC Quality of Life Study Group, Brussels.